Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J Plans 10 Blockbuster Approvals by 2021

In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.

Read More »

Valeant prices psoriasis treatment at $3,500 per month

Canadian drugmaker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.

Read More »

Oral OTEZLA (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Encouraging results were reported from UNVEIL, the first trial of patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy.

Read More »

Guselkumab Outperforms Humira In Study

Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.

Read More »

FDA approves Valeant’s drug to treat plaque psoriasis

The U.S. Food and Drug Administration approved Valeant Pharmaceuticals International’s Siliq to treat adults with moderate-to-severe plaque psoriasis.

Read More »

Novartis Enbrel copy delayed until at least 2018

The Novartis copy of Amgen’s blockbuster drug Enbrel will not go on sale until at least 2018 because of the U.S. company’s patent protection challenge.

Read More »

Allergan to buy Acelity’s tissue unit LifeCell

Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.

Read More »

Pfizer to ship Remicade biosimilar in November

Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.

Read More »

FDA approves J&J’s Stelara for Crohn’s disease

Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.

Read More »

Allergan to Acquire Vitae Pharmaceuticals

Allergan plc will acquire Vitae Pharmaceuticals Inc. for $21.00 per share, in cash, for a total transaction value of approximately $639 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom